Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Moderna (MRNA) has clearly outperformed after announcing an Oct. 24 presentation that will include additional late-stage trial data for its cancer shot developed with Merck (MRK), even as analysts ...

Moderna (MRNA) stock sinks as investors await an Oct. 24 presentation containing additional Phase 3 data for its cancer shot ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.

Shares of vaccine maker Moderna ($MRNA) rose by about 4.5% in Thursday trading as investors looked ahead to an October 24 presentation of detailed cancer trial ...

Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Moderna isn't the only mRNA biotech stock that could deliver big gains for investors. BioNTech(NASDAQ: BNTX) has billions in ...

A study by Australian researchers compared three mRNA-LNP vaccine platforms in human blood samples, generating findings that ...